International Journal of Hematology

, Volume 96, Issue 2, pp 247–253

Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan

  • Mihoko Yotsumoto
  • Shotaro Hagiwara
  • Atsushi Ajisawa
  • Junko Tanuma
  • Tomoko Uehira
  • Hirokazu Nagai
  • Yuko Fujikawa
  • Shunichi Maeda
  • Kiyoshi Kitano
  • Nobuyoshi Arima
  • Kenji Uno
  • Toshiki Iwai
  • Igen Hongo
  • Yasunori Ota
  • Katsuyuki Fukutake
  • Seiji Okada
Original Article

DOI: 10.1007/s12185-012-1127-5

Cite this article as:
Yotsumoto, M., Hagiwara, S., Ajisawa, A. et al. Int J Hematol (2012) 96: 247. doi:10.1007/s12185-012-1127-5

Abstract

The incidence of Hodgkin lymphoma (HL) is paradoxically increasing in the combination anti-retroviral therapy (cART) era. However, there has been no nationwide survey of human immunodeficiency virus (HIV)-associated HL (HIV-HL) in Japan. We retrospectively examined the clinical characteristics and outcomes of 19 newly diagnosed HIV-HL patients at 11 HIV/AIDS and hematology regional hospitals in Japan between 1991 and 2010. At the time of HL diagnosis, 79 % of patients were receiving cART. All the patients, but one received HL diagnoses in the cART era. The median CD4+ cell count at HIV-HL diagnosis was 169/μl. Mixed-cellularity classical Hodgkin lymphoma was the most common subtype occurring in 68 % of the patients; 89 % of the patients were positive for Epstein–Barr virus. Of these 19 patients, 84 % were in advanced stages, with bone marrow involvement observed in 47 % of the patients; 58 % had extranodal sites. All the treated patients were given cART concurrent with HL therapy. The complete remission rate of the treated patients was 87 %. The median OS of the entire cohort was 17 months. These results suggest that the characteristics of HIV-HL in Japan are more aggressive than those of non-HIV-associated HL in Japan, but standard chemotherapy is effective and feasible.

Keywords

Hodgkin lymphomaHIV infectionABVDAntiretroviral therapyEBV

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  • Mihoko Yotsumoto
    • 1
  • Shotaro Hagiwara
    • 2
  • Atsushi Ajisawa
    • 3
  • Junko Tanuma
    • 4
  • Tomoko Uehira
    • 5
  • Hirokazu Nagai
    • 6
  • Yuko Fujikawa
    • 7
  • Shunichi Maeda
    • 8
  • Kiyoshi Kitano
    • 9
  • Nobuyoshi Arima
    • 10
  • Kenji Uno
    • 11
  • Toshiki Iwai
    • 12
  • Igen Hongo
    • 13
  • Yasunori Ota
    • 14
  • Katsuyuki Fukutake
    • 1
  • Seiji Okada
    • 15
  1. 1.Department of Laboratory MedicineTokyo Medical UniversityTokyoJapan
  2. 2.Division of HematologyNational Center for Global Health and MedicineTokyoJapan
  3. 3.Division of Infectious DiseaseTokyo Metropolitan Cancer and Infectious Disease Center, Komagome HospitalTokyoJapan
  4. 4.AIDS Clinical CenterNational Center for Global Health and MedicineTokyoJapan
  5. 5.Department of Infectious DiseaseNational Hospital Organization Osaka National HospitalOsakaJapan
  6. 6.Department of HematologyNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  7. 7.Division of Internal MedicineNagano Prefectural Foundation of Agricultural Cooperative for Health and Welfare, Saku Central HospitalNaganoJapan
  8. 8.Division of ChemotherapyHachinohe City HospitalAomoriJapan
  9. 9.Division of Internal MedicineMatsumoto Medical CenterNaganoJapan
  10. 10.Department of HematologyThe Tazuke Kofukai Medical Research Institute, Kitano HospitalOsakaJapan
  11. 11.Center for Infectious DiseasesNara Medical University HospitalNaraJapan
  12. 12.Division of HematologyKyoto First Red Cross HospitalKyotoJapan
  13. 13.Division of Infectious DiseaseMusashino Red Cross HospitalTokyoJapan
  14. 14.Division of PathologyToranomon HospitalTokyoJapan
  15. 15.Center for AIDS ResearchKumamoto UniversityKumamotoJapan